345 related articles for article (PubMed ID: 36171879)
1. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
Front Genet; 2022; 13():938510. PubMed ID: 36171879
[No Abstract] [Full Text] [Related]
2. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis-related gene HIC1 in the prediction of the prognosis and immunotherapeutic efficacy with immunological activity.
Wu Y; Lin Z; Tang X; Tong Z; Ji Y; Xu Y; Zhou Z; Yang J; Li Z; Liu T
Front Immunol; 2023; 14():1182030. PubMed ID: 37388742
[TBL] [Abstract][Full Text] [Related]
6. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
10. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
11. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
12. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
14. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
15. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
Front Oncol; 2021; 11():607224. PubMed ID: 34026603
[TBL] [Abstract][Full Text] [Related]
16. A Pan-Cancer Analysis Reveals the Prognostic and Immunotherapeutic Value of Stanniocalcin-2 (STC2).
Jiang ZH; Shen X; Wei Y; Chen Y; Chai H; Xia L; Leng W
Front Genet; 2022; 13():927046. PubMed ID: 35937984
[No Abstract] [Full Text] [Related]
17. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value and immunological role of CD44 in pan-cancer study.
Chen S; Zhang S; Chen S; Ma F
Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
[TBL] [Abstract][Full Text] [Related]
19. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
Front Genet; 2022; 13():1068462. PubMed ID: 36712872
[No Abstract] [Full Text] [Related]
20. Pan-cancer analysis of the disulfidptosis-related gene
Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
